Clearbridge Investments LLC Trims Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Clearbridge Investments LLC cut its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 31.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 369,151 shares of the medical equipment provider's stock after selling 171,891 shares during the period. Clearbridge Investments LLC owned approximately 0.53% of Lantheus worth $33,024,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in LNTH. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the third quarter valued at approximately $25,000. Kestra Investment Management LLC purchased a new position in Lantheus during the 4th quarter valued at $27,000. Summit Securities Group LLC purchased a new position in Lantheus during the 4th quarter valued at $37,000. UMB Bank n.a. grew its position in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after acquiring an additional 134 shares during the last quarter. Finally, Parkside Financial Bank & Trust grew its position in Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after acquiring an additional 280 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several research analyst reports. Truist Financial lifted their target price on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. JMP Securities reiterated a "market outperform" rating and set a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group started coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price on the stock. Finally, B. Riley decreased their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $129.43.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,109 shares of company stock worth $6,110,806. 2.00% of the stock is owned by insiders.

Lantheus Stock Down 6.5 %

Shares of NASDAQ LNTH traded down $6.29 during mid-day trading on Friday, reaching $90.92. 1,158,346 shares of the company were exchanged, compared to its average volume of 946,182. The stock has a market cap of $6.23 billion, a price-to-earnings ratio of 15.13 and a beta of 0.38. The firm has a 50-day moving average of $93.31 and a 200 day moving average of $96.03. Lantheus Holdings, Inc. has a 1 year low of $58.46 and a 1 year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. On average, equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.